Multiplex TB/HIV Assay

About NanoPin Technologies

NanoPin Technologies, founded in 2017 and headquartered in San Diego, is a private diagnostics company pioneering a nanoparticle-based platform for infectious disease detection. Its core innovation involves proprietary antibody-conjugated nanoparticles that bind to disease-specific antigen peptides present only during active infection, enabling sensitive blood-based diagnosis. The company's lead efforts target the global tuberculosis epidemic, with assays also developed for HIV and COVID-19, and it has established a key collaboration with Thermo Fisher Scientific. NanoPin operates in the Laboratory Developed Test (LDT) market while advancing its platform for broader applications.

Therapeutic Areas